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numerical data were analysed using the programme Statistica 12.
The study was approved by the Ethical Committee of the Medical University of Lodz, decision RNN/351/17/ KE dated November 21 st , 2017.
Results
All tumours were diagnosed before surgery as nonfunctioning pituitary adenomas. In one case concerning a 54-year-old woman with extremely high FSH and LH elevation a suggestion of gonadotropinoma diagnosis was included into anamnesis.
As shown in 'Materials and Methods', the gonadotropin-expressing pituitary adenomas affect mainly middle-aged and older patients. There is some tendency towards younger mean age in the males, but the difference with female patients is not statistically significant. The frequency of gonadotropin-expressing adenomas in both sexes is similar. In 36 adenomas the immunopositivity concerned LH and in 13 adenomas the immunopositivity concerned FSH. In six adenomas both gonadotropins were present. Moreover, in 11 cases of LH-immunopositive and in one case of FSH-immunopositive tumour, the immunoreaction for αSU was lacking. We concluded that those adenomas presented the expression of free β subunits. In patients with LH-positive adenomas only one (a 54-year-old woman) had elevated LH in blood serum (51.5 mU/ml). The remaining patients with LH-positive tumours presented normal or even decreased serum LH concentrations (Table I) , in spite of the fact that this group included 12 women of menopausal or postmenopausal age. The mean value of LH concentrations in patients with LH-positive tumours is slightly higher than in free β-LH subunit expressing or in LH-negative adenomas, but the differences between the means are not statistically significant. In 12 patients exhibiting FSH immunopositivity of adenoma, in the majority of cases (seven women and one man) serum FSH concentrations were elevated. All these women were in the postmenopausal age (> 50 years). In the remaining four cases of FSH-positive tumours, serum concentration of FSH was normal or decreased (Table II) . Excluding one case of a 72-year-old woman, the three remaining cases concerned men. In one case we suspect the expression of free β-FSH subunit because of the lack of αSU immunostaining. In patients with FSH-negative tumours no elevation of serum FSH was observed. In the remaining 30 patients serum FSH concentrations were situated within normal limits, and in five cases they were decreased. Eleven cases concerned women, and all of them in menopausal or post-menopausal age. The mean value of FSH concentrations in patients with
Introduction
Initially, gonadotropin expressing tumours (gonadotropinomas) were considered as a very rare subtype of pituitary adenoma. The specific clinical symptoms of these tumours were rarely observed. Precocious puberty in young boys, ovarian overstimulation in young women, and testicular enlargement in adult men were occasionally reported [1] [2] [3] . In the aged people no specific clinical symptoms of gonadotropinoma were observed, and those tumours are classified as non-functioning pituitary adenomas (NFPA). However, when immunohistochemical investigation with antibodies against pituitary hormones became a routine and obligatory procedure of pathomorphological examination of excised pituitary tumours, it was found that the vast majority of NFPA express gonadotropins or their subunits [4] [5] [6] [7] [8] . Moreover, it was recently shown, on the basis of molecular and in vitro studies, that even the adenomas totally immunonegative for pituitary hormones (null cell adenomas -NCA) express gonadotropins [9] . However, according to our knowledge, the systematic studies comparing the presurgical serum concentrations of follitropin (FSH), lutropin (LH), and α-subunit (αSU) with immunoreactivity of the above-mentioned hormones in post-surgical samples are still lacking.
Material and methods
Archival material of 165 immunohistochemically examined pituitary adenomas was included in the study. FSH and LH were detected using anti-FSH and anti-LH monoclonal antibodies (DAKO Denmark or Chemicon MERCK) and αSU with anti-αSU monoclonal antibody (Immunotech France). The visualisation of immunostaining was performed using an Envision kit (DAKO Denmark) with the use of 3,3' diaminobenzidine (DAB) as chromogen.
In 78 tumours positive immunostaining for FSH, LH, and/or their free β-subunits was found; in 43 cases (21 women and 22 men) clinical documentation, including the results of gonadotropin measurement in blood serum before surgery, was available. FSH and LH were measured by means of chemiluminescence method (OCD Johnson & Johnson, UK). Additionally, in 21 cases (9 women and 12 men) αSU concentration was examined using IRMA (Immunotech, France) method. The female patients were aged 41-73 years (mean age 60.0 ± 9 years), and males were aged 39-77 years (mean age 55.8 ± 11 years). In the patients the confrontation of the results of the immunohistochemical study and of FSH, LH, and αSU measurements in peripheral blood serum was performed. The
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FSH-positive tumours is over twofold higher than in those with FSH-negative adenomas. However, the difference is not statistically significant because of a high dispersion of the results. In 21 cases, in addition to FSH and LH, the αSU concentration was measured (Table III) . The elevated αSU concentration was observed in 3/15 cases (20%) of αSU-positive tumours. In contrast, in anyone of the patients with αSU-negative adenomas an elevated αSU concentration was observed. The mean values of αSU concentrations in αSU-positive adenomas were higher than in cases of α-SU-negative adenomas, but the difference is not statistically significant.
Discussion
The data presented above support the view that while hormonally active gonadotropinomas are rare, the vast majority of non-functioning pituitary tumours (NFPA) express gonadotropins [4] [5] [6] [7] [8] . Our findings confirm the statement that FSH hypersecretion is more frequent than that of LH [10] . However, the positive immunostaining for LH, and specifically for the free β-LH subunit, is more frequent in comparison with FSH. Since the frequency of NFPA constitutes approximatively 30% of all pituitary tumours [6, 7, 10] , it means that gonadotropinomas can be estimated for about 20% of all pituitary adenomas. This value is compatible with earlier published data (24% according to [10] ). A question that remains to be answered is the proportion of "active (over-secreting)" versus the "silent" gonadotropinomas (i.e. the gonadotropinomas not manifesting themselves by enhanced gonadotropin levels). The answer is not simple because reliable determination of whether the elevated FSH is of tumoural origin or generated by the remaining non-tumoural pituitary is not possible. However, the women with FSH-negative tumours, in spite of the postmenopausal age, did not present, in any case, elevation of serum FSH. This finding speaks in favour of tumoural origin of elevated FSH in patients with FSH-positive adenomas. If we consider all nine of the cases of gonadotropin over-secretion observed in our study, the frequency of "active" gonadotropinomas could be estimated for approximately 21% of the all gonadotropin-expressing tumours, and for 4.2% of the pituitary adenomas in general. As expected, the vast majority of gonadotropinomas (mostly expressing LH or free β-LH) are "silent". The causes of this phenomenon are not known, but it could be hypothesised that they may result -at least in part -from the absence of the α-subunit or the lack of the mutual junction between α and β subunits. This 
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is supported not only by the frequent expression of free β-LH, but also by the disproportion of LH, FSH, and αSU immunostained cells often observed in these adenomas. This presumption is also supported by the observation of the presence of the frequent detection of free subunits: mainly β-LH subunit, more rarely free β-FSH [11] . The possibilities of correct presurgical diagnosis of gonadotropinoma, especially in middle-aged and elderly people, remain limited. The determination of FSH, LH, and αSU in blood before surgery should be obligatory, but is usually insufficient because very low or even undetectable levels of these substances do not exclude the diagnosis of gonadotropinoma. According to some recent publications, presurgical diagnosis might be improved by the measurement of αSU after thyroliberin (TRH) administration [12, 13] . However, the sensitivity of this test may be limited because of the absence of αSU in many tumours.
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